Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03611569 · ClinicalTrials.gov registry record · Phase 1
Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease
A Phase 1 study, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
NCT03611569 is a Phase 1 study that has completed, run by H. Lundbeck A/S. The registered enrollment target is 74 participants.
The verdict
NCT03611569, a Phase 1 study, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety of a single dose of Lu AF82422, how well it is tolerated, how the drug effects the body and what the body does to the drug in healthy non-Japanese and Japanese subjects and in patients with Parkinson's disease
Interventions
- DRUG Placebo
- DRUG Lu AF82422
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2018-07-25 |
| Est. Completion | 2021-07-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03611569
The ClinicalTrials.gov registry entry for NCT03611569 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03611569 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03611569 about?
NCT03611569 is a clinical study titled "Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease". The purpose of this study is to investigate the safety of a single dose of Lu AF82422, how well it is tolerated, how the drug effects the body and what the body does to the drug in healthy non-Japanese and Japanese subjects and in patients with Parkinson's disease
What is the current status of trial NCT03611569?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2018-07-25. Estimated completion is 2021-07-26.
What interventions are being tested in trial NCT03611569?
The interventions under investigation include: Placebo (DRUG), Lu AF82422 (DRUG).
Who is sponsoring clinical trial NCT03611569?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.